ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.210,48
0,58%
S&P 500
5.187,70
0,13%
US Dollar vs BRL
5,0747
0,00%
Bitcoin
62.424,58
0,14%
Brent Oil
82,325
-0,65%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. AMEX
  6. Hemispherx Biopharma Inc New (HEB)

  7. Hemispherx Biopharma Inc New (HEB) Notícias

HEB

Hemispherx Biopharma (HEB)

Hemispherx Biopharma Inc New
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:AMEX:HEB
DataHoraFonteTítuloCódigoCompanhia
05/06/202018:00Edgar (US Regulatory)Current Report Filing (8-k)AMEX:HEBHemispherx Biopharma Inc New
14/05/202009:21Edgar (US Regulatory)Amended Quarterly Report (10-q/a)AMEX:HEBHemispherx Biopharma Inc New
30/03/202018:24Edgar (US Regulatory)Annual Report (10-k)AMEX:HEBHemispherx Biopharma Inc New
10/03/202018:20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:HEBHemispherx Biopharma Inc New
14/02/202019:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:HEBHemispherx Biopharma Inc New
31/01/202015:46Edgar (US Regulatory)Statement of Ownership (sc 13g)AMEX:HEBHemispherx Biopharma Inc New
02/01/202013:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:HEBHemispherx Biopharma Inc New
14/11/201918:35Edgar (US Regulatory)Quarterly Report (10-q)AMEX:HEBHemispherx Biopharma Inc New
26/09/201918:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)AMEX:HEBHemispherx Biopharma Inc New
26/09/201907:01Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:HEBHemispherx Biopharma Inc New
25/09/201907:02Edgar (US Regulatory)Securities Registration Statement (s-1/a)AMEX:HEBHemispherx Biopharma Inc New
20/09/201912:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:HEBHemispherx Biopharma Inc New
06/09/201918:02Edgar (US Regulatory)Securities Registration Statement (s-1)AMEX:HEBHemispherx Biopharma Inc New
23/08/201907:50GlobeNewswire Inc.Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoin...AMEX:HEBHemispherx Biopharma Inc New
20/08/201917:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:HEBHemispherx Biopharma Inc New
15/08/201907:45GlobeNewswire Inc.Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical TrialsAMEX:HEBHemispherx Biopharma Inc New
08/08/201907:50GlobeNewswire Inc.Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®AMEX:HEBHemispherx Biopharma Inc New
02/08/201907:45GlobeNewswire Inc.Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribut...AMEX:HEBHemispherx Biopharma Inc New
28/06/201917:06Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)AMEX:HEBHemispherx Biopharma Inc New
28/06/201908:00GlobeNewswire Inc.Hemispherx Biopharma CFO Adam Pascale Announces RetirementAMEX:HEBHemispherx Biopharma Inc New
25/06/201913:18Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)AMEX:HEBHemispherx Biopharma Inc New
18/06/201917:05Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:HEBHemispherx Biopharma Inc New
17/06/201909:30GlobeNewswire Inc.Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology ProgramAMEX:HEBHemispherx Biopharma Inc New
12/06/201916:31GlobeNewswire Inc.Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combinat...AMEX:HEBHemispherx Biopharma Inc New
31/05/201911:16GlobeNewswire Inc.Hemispherx Biopharma Stockholders Approve Reverse Stock SplitAMEX:HEBHemispherx Biopharma Inc New
16/05/201909:30GlobeNewswire Inc.Hemispherx Reports 2019 First Quarter Financial ResultsAMEX:HEBHemispherx Biopharma Inc New
13/05/201913:22GlobeNewswire Inc.Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx BiopharmaAMEX:HEBHemispherx Biopharma Inc New
13/05/201909:30GlobeNewswire Inc.Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer CenterAMEX:HEBHemispherx Biopharma Inc New
08/05/201909:30GlobeNewswire Inc.Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of BiotechnologyAMEX:HEBHemispherx Biopharma Inc New
06/05/201909:30GlobeNewswire Inc.Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen CommercializationAMEX:HEBHemispherx Biopharma Inc New
 Apresentando as notícias mais relevantes sobre:AMEX:HEB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
ETER3
ETERNIT ON
BOV
AZEV4
AZEVEDO PN
BOV
VVEO3
CM Hospitalar ON
BOV
CRFB3
CARREFOUR ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados